Counseling<unk> , like many sexual dysfunctions, is something that people are treated for in the context of a relationship. Theoretically, one could be diagnosed with and treated for<unk>  without being in a relationship. However, relationship status is the most predictive factor accounting for distress in women with low<unk>  and distress is required for a diagnosis of<unk> . Therefore, it is common for both partners to be involved in therapy. Typically, the therapist tries to find a psychological or biological cause of the<unk> . If the<unk>  is organically caused, the clinician may try to treat it. If the clinician believes it is rooted in a psychological problem, he or she may recommend therapy. If not, treatment generally focuses more on relationship and communication issues, improved communication (verbal and nonverbal), working on non-sexual intimacy, or education about sexuality may all be possible parts of treatment. Sometimes problems occur because people have unrealistic perceptions about what normal sexuality is and are concerned that they do not compare well to that, and this is one reason why education can be important. If the clinician thinks that part of the problem is a result of stress, techniques may be recommended to more effectively deal with that. Also, it can be important to understand why the low level of sexual<unk>  is a problem for the relationship because the two partners may associate different meanings with sex but not know it. In the case of men, the therapy may depend on the subtype of<unk> . Increasing the level of sexual<unk>  of a man with lifelong/generalized<unk>  is unlikely. Instead, the focus may be on helping the couple to adapt. In the case of acquired/generalized, it is likely that there is some biological reason the clinician can address. In the case of acquired/situational, some form of psychotherapy may be used, possibly with the man alone and possibly together with his partner. Medication Approved Flibanserin was the first medication approved by FDA for the treatment of<unk>  in pre-menopausal women. Its approval was controversial and a systematic review found its benefits to be marginal. The only other medication approved in the US for<unk>  in pre-menopausal women is bremelanotide, in 2019. Off-label A few studies suggest that the antidepressant, bupropion, can improve sexual function in women who are not depressed, if they have<unk> . The same is true for the anxiolytic, buspirone, which is a 5-HT1A receptor agonist similarly to flibanserin. Testosterone supplementation is effective in the short term. However, its long-term safety is unclear.
Hypoactive sexual desire disorder
Sexual arousal disorder
Persistent genital arousal disorder
Female sexual arousal disorder
Psychosexual disorder
Gratification disorder
Sexual addiction
Sexual relationship disorder